SCHEMBL17624441

SCHEMBL17624441

CN1Cc2cc(C(F)(F)F)cnc2C1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 7/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
LMNA P02545 1/20 0.40
HRH4 Q9H3N8 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
SSTR4 P31391 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
SPR P35270 1/20 0.36
POLB P06746 1/20 0.36
AGBL2 Q5U5Z8 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
APAF1 O14727 1/20 0.34
MAPT P10636 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2743273 0.87 CYP2C19 (0.41) SLC6A9SMN1; SMN2LMNAHRH4HRH3
SCHEMBL12341045 0.84 HPGD (0.34) SLC6A9HRH3KDM4EMAPT
SCHEMBL19504489 0.81 SLC6A9 (0.39) SLC6A9SMN1; SMN2LMNASSTR4KMT2A
SCHEMBL20651758 0.80 SLC6A9 (0.43) SLC6A9SMN1; SMN2HRH3KMT2AALDH1A1
SCHEMBL18711788 0.78 SLC6A9 (0.51) SLC6A9SMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL20210923 0.77 SLC6A9 (0.38) SLC6A9SMN1; SMN2LMNASSTR4KMT2A
SCHEMBL27700994 0.77 SLC6A9 (0.50) SLC6A9SMN1; SMN2LMNAALDH1A1SPR
SCHEMBL18702206 0.76 SLC6A9 (0.49) SLC6A9SMN1; SMN2LMNASSTR4ALDH1A1
SCHEMBL19080449 0.76 SLC6A2 (0.34) SMN1; SMN2SSTR4
SCHEMBL27815254 0.75 SLC6A9 (0.46) SLC6A9SMN1; SMN2LMNASSTR4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023107630-A2 AMINO ALCOHOL COMPOUNDS AND USES THEREOF Kineta, Inc. (US) 2023-06-15 WO disclosed
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-26 US disclosed
WO-2017117447-A1 MULTICYCLIC COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2017-07-06 WO disclosed
WO-2016044604-A1 CARM1 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305922-A1 CARM1 INHIBITORS AND USES THEREOF CARM1, ADRM1, PRMT1 SLC6A9 4847/4885SMN1; SMN2 1375/4885LMNA 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.